LivaNova plc (LIVN) Misses Q1 EPS by 10c, Revenues Miss; Updated FY20 EPS Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Livanova (LIVN) PT Lowered to $65 at Piper Sandler
April 29, 2020 3:39 PM EDTPiper Sandler analyst Matt O'Brien lowered the price target on Livanova (NASDAQ: LIVN) to $65.00 (from $80.00) while maintaining an Overweight rating.
negative commentary and outlook but lots value trapped in the stock... MoreLivaNova plc (LIVN) Bi-Flow Cannula Receives CE Mark for ECMO Applications
April 27, 2020 9:07 AM EDTLivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned CE Mark approval for ECMO procedures where femoral artery cannulation can be applied. Bi-Flow previously received CE Mark in 2019 for cardiac surgery procedures requiring femoral artery cannulation. Now validated for up to 29 days of use, Bi-Flow ECMO is designed to reduce the risk of limb ischemia for patients receiving ECMO and it allows for safe, easy and reproducible procedures.
After witnessing the potential of Bi-Flow in the cardiac surgery setting, the... More
